BRNS
Barinthus Biotherapeutics plc
NASDAQ: BRNS · HEALTHCARE · BIOTECHNOLOGY
$0.60
-1.66% today
Updated 2026-04-29
Market cap
$26.23M
P/E ratio
—
P/S ratio
2.17x
EPS (TTM)
$-1.64
Dividend yield
—
52W range
$1 – $3
Volume
0.0M
Barinthus Biotherapeutics plc (BRNS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-18.76M | $-11.03M | $-32.58M | $-14.43M | $-50.92M | $-28.94M | $-47.98M |
| Capital expenditures | $128347.00 | $293000.00 | $1.15M | $6.14M | $5.41M | $892000.00 | $37000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | — | $3.63M | $16.49M | $9.88M | $5.05M | $4.71M | $468000.00 |
| Free cash flow | $-18.89M | $-11.32M | $-33.73M | $-20.57M | $-56.34M | $-29.83M | $-48.02M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $177.25M | — | — | — | — |